Highest-materiality recent filing
TransCode Phase 1a TTX-MC138 trial meets safety endpoint; 64% stable disease at 6 months
16 patients received 86 doses; median treatment 11.3 weeks (range 4-52.4 weeks).
TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity
Stockholders' equity reported at $1.25M as of March 31, 2026, below Nasdaq's $2.5M minimum.
Stockholders' equity as of March 31, 2026 was $1,251,427, below Nasdaq's $2,500,000 minimum requirement.
TransCode secures up to $20M flexible financing from Yorkville via SEPA and convertible notes
Up to $14M SEPA for common stock sales at 97% of lowest 3-day VWAP; up to $6M in pre-paid convertible notes at 5% discount.
TransCode acquires exclusive license to oncolytic immunotherapy platform in all-stock deal
Issued 1,136,364 shares of Series C non-voting convertible preferred to Unleash; convertible to common after stockholder approval.
TransCode submits IND amendment for Phase 2a trial of TTX-MC138 in colorectal cancer
IND amendment filed with FDA for Phase 2a dose-expansion trial of TTX-MC138 in colorectal cancer patients with ctDNA-positive MRD.
TransCode publishes preclinical data showing TTX-MC138 improves survival in glioblastoma models
Study in Journal of Functional Biomaterials shows TTX-MC138 delivered to GBM tumors after IV injection.
ABCJ (parent of Polynoma) reported 2024 net loss of $16.4M and accumulated deficit of $193M.
TransCode partners with Quantum Leap for Phase 2a trial of TTX-MC138 in colorectal cancer
Collaboration with Quantum Leap to evaluate TTX-MC138 in PRE-I-SPY Phase 2a dose-expansion trial.
Each share of common stock held as of Oct 20, 2025 receives one CVR; CVRs pay 50% of Net Proceeds from future Upfront or Milestone payments on TTX-MC138 program disposals.
TransCode completes Phase 1a of TTX-MC138; 44% stable disease rate, moves to Phase 2a
16 patients treated across 4 dose levels; no dose-limiting toxicities or significant safety events observed.
TransCode acquires ABCJ from CK Life Sciences unit; raises $25M in concurrent investment
Acquired 100% of ABCJ from DEFJ (CK Life Sciences sub) for 83,285 common and 1,152.9568 Series A Preferred shares.
TransCode acquires ABCJ, gets $25M investment from DEFJ, appoints new CEO
Acquired 100% of ABCJ for 83,285 common shares (9.99% of pre-close), convertible preferred, and up to $95M milestone payments.
TransCode receives Nasdaq delisting notice; plans to appeal bid-price deficiency
Company received Nasdaq notice on May 6, 2025 for failing to maintain $1.00 minimum bid price for 30 consecutive days (Mar 24–May 5).
TransCode Therapeutics announces 1-for-28 reverse stock split effective May 15, 2025
Reverse split at 1-for-28 ratio; effective 12:01 a.m. ET on May 15, 2025.
TransCode Therapeutics announces 1-for-28 reverse stock split to regain Nasdaq compliance
Stockholders approved 1-for-28 reverse split on May 2, 2025; board ratified the ratio.
TransCode announces $10M registered direct offering of 10.25M shares and warrants at $0.98/unit
Gross proceeds of ~$10M from sale of 10.25M shares and 10.25M warrants at $0.98/unit.
TransCode opens Phase 1 Cohort 3; PK/PD from Cohort 1 show 66% miR-10b inhibition at 24h
Safety Review Committee approved third cohort after no significant safety/DLTs in Cohort 2.
TransCode raises ~$8M in private placement; expects to regain Nasdaq compliance
Issued 21.2M shares/pre-funded warrants, 21.2M Series C and 21.2M Series D warrants at $0.377/unit.
TransCode Therapeutics announces 1-for-33 reverse stock split effective Dec 4, 2024
Reverse split ratio 1-for-33; effective 12:01 a.m. ET Dec 4, 2024; new CUSIP 89357L402.
TransCode shareholders approve 10M share offering and reverse stock split at special meeting
Ratified issuance of 10M shares of common stock and warrants to ThinkEquity LLC via best-efforts public offering.
TransCode gets Nasdaq extension to regain compliance; Public Reprimand issued
Nasdaq Hearings Panel granted extension to comply with Bid Price Rule 5550(a)(2), Equity Rule 5550(b), and Shareholder Approval Rule 5635(d).
Nasdaq notifies TransCode of shareholder approval violation; adds to delisting risk
Received new Nasdaq deficiency letter on Sep 23, 2024 for failing to obtain shareholder approval for a deeply discounted offering.
TransCode Therapeutics faces Nasdaq delisting over bid price and equity deficiencies; hearing Oct 1
Minimum Bid Price Deficiency Letter received Aug 13; stock below $1.00 for 30 consecutive days through Aug 12.
TransCode receives two Nasdaq deficiency notices; faces potential delisting
On Aug 13, 2024, Nasdaq notified TransCode of minimum bid price deficiency; stock closed below $1.00 for 30 consecutive days.
TransCode Therapeutics prices $3.0M public offering of 10M shares at $0.30
Offering of 10,000,000 common shares at $0.30 per share for gross proceeds of $3.0M.
TransCode Therapeutics shareholders reject reverse stock split proposal at annual meeting
Reverse stock split proposal failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
TransCode shareholders reject reverse stock split; stock plan amendment approved
Reverse stock split (1:2 to 1:40) failed: 1,018,164 for, 1,277,915 against, 96,498 abstain.
TransCode Therapeutics receives Nasdaq delisting notice; hearing set for June 25, 2024
Nasdaq delisting notice due to failure to maintain minimum $1.00 bid price for 30 consecutive business days.
Received delisting notice on May 7, 2024 for failing to regain compliance with $1.00 minimum bid price rule by May 6 deadline.
TransCode Therapeutics reports FY2023 operating loss of $19.4M; cash $2.8M at year-end
Cash $2.8M as of Dec 31, 2023; net $6.2M raised in Jan 2024; funding expected into late Q3/Q4 2024.
Nasdaq determined TransCode met minimum $2.5M stockholders' equity requirement for continued listing.
TransCode raises $7.25M in public offering; expects to regain Nasdaq equity compliance
Priced public offering of 5,942,623 shares (or pre-funded warrants) and warrants for 11,885,246 shares at $1.22/unit.
TransCode CEO resigns; 1-for-40 reverse stock split effective Jan 16; cash ~$2.8M
CEO Robert Michael Dudley resigned effective Jan 13, 2024; severance of $34,607.70 and option acceleration.
Special meeting Jan 8, 2024: 12,472,113 shares voted of 25,097,596 entitled.
Robert Michael Dudley entered into a separation agreement with the Company pursuant to which he resigned from his position as the Company’s President and Chief Executive Officer, and as a director of the Company, in each case effective January 13, 2024.
Thomas A. Fitzgerald, the Company’s Chief Financial Officer, was appointed to serve as the Company’s Interim President and Chief Executive Officer, effective January 13, 2024.
Max materiality 0.90 · Median 0.65 · Most common event other_material